PHAR 株価分析 — PHARMING GROUP NV (Healthcare >> Biotechnology)
PHAR に関するよくある質問
PHARのPER(株価収益率)は?
PHARMING GROUP NV(PHAR)は現在PER 43.37倍で取引されています。
PHARのROE(自己資本利益率)は?
PHARMING GROUP NVのROEは4.58%です。
PHARの配当利回りは?
PHARMING GROUP NVの配当利回りは0.00%です。
PHARの品質スコア(Quality Score)は?
当社のAIはPHARの総合財務品質を100点中62点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
PHARは今が買い時ですか?
当社AIのタイミングスコアは100点中26点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
PHARはどのセクターに属しますか?
PHARMING GROUP NVはHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
PHAR AI Analysis Summary
Our AI summary for PHAR: PHARMING GROUP NV (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 43.37, ROE of 4.58%, a dividend yield of 0.00%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 10.08
Price
-0.67
(-6.23%)
Day Change
|
|
|---|
PHAR, ファンダメンタルスコアはok ( ファンダメンタル = 62) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
ROEが低い
平均ROEが低い
ROAがROEに比べて低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
50% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
2962
|
| Magic Formula Rank by ROE |
2962
|
| Magic Formula Rank by ROIC |
2310
|
| Price | 10.08 |
| PBV / Sector |
2.83 / 5.20
|
| Earning Per Share | 0.16 |
| PE / Sector |
43.37 / 19.97
|
| PEG or PE/Growth / Sector |
-0.42 / 1.22
|
| Average 1M Daily Value |
0.11 M
GREAT
|
| Average 1W Daily Value |
0.19 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
60% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:19 |
| Symbol | PHAR |
| Name | PHARMING GROUP NV |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 70.78 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 760.86 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Darwinweg 24, Leiden, Netherlands, 2333 CR
Phone: 31 71 524 7400
Website: https://www.pharming.com
Employees: 407
Sector: Healthcare >> Biotechnology
Description: Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K" inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google